Peak Bio awarded patent covering Thailanstatin-ADC platform technology

Peak Bio was awarded US Patent No. 11,691,982 B2 entitled “Thailanstatin Analogs” by The United States Patent and Trademark Office. The new patent describes properties of potent heteroaryl-substituted Thailanstatin payloads, proprietary non-cleavable and cleavable linkers, and antibody-drug conjugate technology derived from it. Peak Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and cancer. The patent granted by the USPTO covers claims for the Company’s potent Thailanstatin payload platform specific to the spliceosome protein, SF3B1. This patent application is a divisional patent of the Company’s R&D toxin portfolio on Thailanstatin, termed PH-1, building on the portfolio of previously issued patents. Grant Patent right for PCT/US2018/051721 family was issued by China National Intellectual Property Administration in Aug 2023, and in Israel in Sept 2023. Corresponding foreign patent applications are pending and currently undergoing examination in PCT countries – Australia, Canada, the European Patent Office, Japan, Mexico, New Zealand, Singapore, and others. Structure-activity-relationship studies for novel compounds and medicinal chemistry routes for their synthesis are also described. This Patent is an important addition to the intellectual property portfolio surrounding the Company’s ADC technology, and significantly enhances the patent position for both internal and future potential partner programs. Peak Bio is developing a differentiated Trop2 PH1 ADC and is investigating collaborations for clinical development and/ or commercialization of this asset along with other collaboration opportunities that incorporate our novel payloads.